My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 153

    1.

    Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.

    Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM; DCCT Skin Collagen Ancillary Study Group.

    Diabetes. 2005 Nov;54(11):3103-11.PMID: 16249432 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial.

    Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S.

    Diabetes. 1999 Apr;48(4):870-80.PMID: 10102706 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes.

    Yu Y, Thorpe SR, Jenkins AJ, Shaw JN, Sochaski MA, McGee D, Aston CE, Orchard TJ, Silvers N, Peng YG, McKnight JA, Baynes JW, Lyons TJ; DCCT/EDIC Research Group.

    Diabetologia. 2006 Oct;49(10):2488-98. Epub 2006 Aug 29.PMID: 16955213 [PubMed - indexed for MEDLINE]Related articles

    4.

    Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.

    Miura J, Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y.

    J Diabetes Complications. 2003 Jan-Feb;17(1):16-21.PMID: 12505751 [PubMed - indexed for MEDLINE]Related articles

    5.

    The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial.

    Lachin JM, Genuth S, Nathan DM, Rutledge BN.

    Diabetes. 2007 Jul;56(7):1913-21. Epub 2007 Mar 14.PMID: 17360979 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

    [No authors listed]

    N Engl J Med. 2000 Feb 10;342(6):381-9. Erratum in: N Engl J Med 2000 May 4;342(18):1376. PMID: 10666428 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes.

    McCarter RJ, Hempe JM, Gomez R, Chalew SA.

    Diabetes Care. 2004 Jun;27(6):1259-64.PMID: 15161772 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.

    Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, Hunsicker LG, Stein G; Collaborative Study Group.

    Am J Kidney Dis. 2006 Oct;48(4):571-9.PMID: 16997053 [PubMed - indexed for MEDLINE]Related articles

    9.

    Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.

    Galler A, Müller G, Schinzel R, Kratzsch J, Kiess W, Münch G.

    Diabetes Care. 2003 Sep;26(9):2609-15.PMID: 12941727 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.

    Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S.

    Curr Pharm Des. 2008;14(10):962-8. Review.PMID: 18473846 [PubMed - indexed for MEDLINE]Related articles

    11.

    Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes.

    Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H.

    Diabetes. 1995 Jul;44(7):824-9.PMID: 7789650 [PubMed - indexed for MEDLINE]Related articles

    12.

    Renal and retinal microangiopathy after 15 years of follow-up study in a sample of Type 1 diabetes mellitus patients.

    Romero P, Salvat M, Fernández J, Baget M, Martinez I.

    J Diabetes Complications. 2007 Mar-Apr;21(2):93-100.PMID: 17331857 [PubMed - indexed for MEDLINE]Related articles

    13.

    Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy.

    Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ.

    J Clin Invest. 1993 Jul;92(1):212-7.PMID: 8325987 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).

    Schiel R, Franke S, Appel T, Voigt U, Ross IS, Kientsch-Engel R, Stein G, Müller UA.

    J Diabetes Complications. 2003 Mar-Apr;17(2):90-7.PMID: 12614975 [PubMed - indexed for MEDLINE]Related articles

    15.

    Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM.

    Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM.

    Diabetes. 1992 Oct;41(10):1286-92.PMID: 1397702 [PubMed - indexed for MEDLINE]Related articles

    16.

    Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats.

    Degenhardt TP, Fu MX, Voss E, Reiff K, Neidlein R, Strein K, Thorpe SR, Baynes JW, Reiter R.

    Diabetes Res Clin Pract. 1999 Feb;43(2):81-9.PMID: 10221660 [PubMed - indexed for MEDLINE]Related articles

    17.

    A novel advanced glycation index and its association with diabetes and microangiopathy.

    Sampathkumar R, Balasubramanyam M, Rema M, Premanand C, Mohan V.

    Metabolism. 2005 Aug;54(8):1002-7.PMID: 16092048 [PubMed - indexed for MEDLINE]Related articles

    18.

    Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes.

    Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, Hanssen KF.

    Diabetes Care. 1999 Jul;22(7):1186-90.PMID: 10388987 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus.

    Garay-Sevilla ME, Regalado JC, Malacara JM, Nava LE, Wróbel-Zasada K, Castro-Rivas A, Wróbel K.

    J Endocrinol Invest. 2005 Mar;28(3):223-30.PMID: 15952406 [PubMed - indexed for MEDLINE]Related articles

    20.

    Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.

    Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP; ACTION I Investigator Group.

    Am J Nephrol. 2004 Jan-Feb;24(1):32-40. Epub 2003 Dec 17.PMID: 14685005 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity